BETAMI–DANBLOCK trial: Beta-blockers are recommended for myocardial infarction and reduced left ventricular ejection fraction, but potential benefits for preserved or mildly reduced ejection fraction are unclear. Research findings are summarized in a new Quick Take video.
nej.md/41DqahQ
ALT Visual representation of the BETAMI–DANBLOCK trial, which evaluated beta-blockers for preserved or mildly reduced ejection fraction.